Karuna Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Karuna Therapeutics şirketinin kazançları yıllık ortalama -51.9% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 46.1% oranında artan oldu.

Anahtar bilgiler

-51.9%

Kazanç büyüme oranı

105.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	46.1%
Özkaynak getirisi	-34.6%
Net Marj	-66,311.9%
Son Kazanç Güncellemesi	31 Dec 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Feb 20

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 06

Best Performing Stocks

Sep 23

Karuna Therapeutics: This Ship Has Sailed

Sep 09

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Aug 08

Karuna Therapeutics: Front-Running KarXT Phase 3

Jun 26

Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans

May 10

Gelir ve Gider Dağılımı

Karuna Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:KRTX Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Dec 23	1	-434	131	364
30 Sep 23	6	-396	108	348
30 Jun 23	6	-354	95	306
31 Mar 23	11	-316	85	266
31 Dec 22	11	-276	75	224
30 Sep 22	42	-228	71	203
30 Jun 22	42	-202	65	180
31 Mar 22	37	-172	57	152
31 Dec 21	37	-144	52	128
30 Sep 21	0	-140	41	97
30 Jun 21	0	-108	36	71
31 Mar 21	0	-90	33	57
31 Dec 20	0	-69	28	43
30 Sep 20	0	-52	23	33
30 Jun 20	0	-43	21	26
31 Mar 20	0	-41	22	22
31 Dec 19	0	-44	21	25
30 Sep 19	0	-45	18	26
30 Jun 19	0	-42	15	22
31 Mar 19	0	-27	7	17
31 Dec 18	0	-18	3	12

Kaliteli Kazançlar: KRTX şu anda kârlı değil.

Büyüyen Kar Marjı: KRTX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: KRTX kârlı değildir ve zararlar son 5 yılda yılda 51.9% oranında artmıştır.

Büyüme Hızlandırma: KRTX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: KRTX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: KRTX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -34.58% ) sahiptir.

Karuna Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022)

Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Recent updates

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Karuna Therapeutics: Getting Sold Short

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.2% to US$327

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 23%

Consensus revenue estimates decrease by 22%

Price target increased by 9.9% to US$291

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Karuna Therapeutics, Inc. Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

New minor risk - Profitability

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for Karxt for the Treatment of Schizophrenia

Karuna Therapeutics, Inc. Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 55%

New minor risk - Profitability

Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022)

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for Karxt for the Treatment of Schizophrenia

We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely

Director exercised options and sold US$2.5m worth of stock

New minor risk - Profitability

Karuna Therapeutics, Inc. Announces Chief Financial Officer Changes

Director exercised options and sold US$2.6m worth of stock

Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Director notifies of intention to sell stock

We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate

CFO & Secretary notifies of intention to sell stock

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

Consensus revenue estimates increase by 20%

Co-Founder & COO notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Independent Director exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$920k worth of stock

Consensus revenue estimates fall by 85%

CFO & Secretary notifies of intention to sell stock

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Independent Director exercised options and sold US$113k worth of stock

CFO & Secretary exercised options to buy US$2.3m worth of stock.

Chief Medical Officer exercised options and sold US$965k worth of stock

Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023

Co-Founder & COO exercised options and sold US$168k worth of stock

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates fall by 25%

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Co-Founder & COO exercised options and sold US$444k worth of stock

Chief Medical Officer exercised options and sold US$992k worth of stock

CFO & Secretary notifies of intention to sell stock

CFO & Secretary recently sold US$3.4m worth of stock

Best Performing Stocks

Chief Medical Officer exercised options and sold US$1.2m worth of stock

Karuna Therapeutics: This Ship Has Sailed

Consensus forecasts updated

Price target increased to US$236

Karuna Therapeutics, Inc. Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

High number of new directors

Chief Medical Officer exercised options and sold US$1.9m worth of stock